Anavex Life Sciences Corp. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM
CURRENT REPORT
Pursuant
to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
| (State or other jurisdiction | (Commission | (IRS Employer |
| of incorporation) | File Number) | Identification No.) |
(Address of principal executive offices) (Zip Code)
1-
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of Each Class | Trading Symbol | Name of Each Exchange on Which Registered | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth
company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On July 3, 2025 and effective July 5, 2025, Anavex Life Sciences Corp., a Nevada corporation (the “Company”), entered into the Fourth Amendment to Employment Agreement (the “Missling Amendment”) with Christopher Missling, PhD, in his continuing capacity as Chief Executive Officer of the Company. The Missling Amendment amends the Employment Agreement by and between the Company and Dr. Missling, dated June 27, 2013, as most recently amended by the Third Amendment to Employment Agreement dated April 7, 2022 (as amended, the “Missling Employment Agreement”).
The Missling Amendment is made to extend the term of the Missling Employment Agreement through July 5, 2028, unless earlier terminated as provided in the Missling Amendment. Pursuant to the terms of the Missling Amendment, beginning July 5, 2025, Dr. Missling shall receive an annual base salary of $800,000 and is eligible to earn an annual cash target bonus for each whole or partial calendar year of twenty percent of his base salary and an annual equity grant in an amount to be determined by the compensation committee of the Company’s board of directors.
Additionally, effective July 3, 2025, the Company entered into the Third Amendment to Employment Agreement (the “Boenisch Amendment”) with Sandra Boenisch, in her continuing capacity as Principal Financial Officer of the Company. The Boenisch Amendment amends the Amended and Restated Employment Agreement by and between the Company and the PFO dated October 4, 2017, as most recently amended by the Second Amendment to Employment Agreement dated February 28, 2022 (as amended, the “Boenisch Employment Agreement”).
The Boenisch Amendment provides that the term of the Boenisch Employment Agreement shall continue indefinitely, unless terminated as provided in the Boenisch Amendment. Pursuant to the terms of the Boenisch Amendment, Ms. Boenisch shall receive an annual base salary of $279,840 Canadian Dollars and is eligible to earn an annual cash target bonus for each calendar year of twenty percent of her base salary. The Boenisch Amendment also amended the termination provisions of the Boenisch Employment Agreement, including to increase the amount of severance owed to Ms. Boenisch if she is terminated without cause from six (6) months to twelve (12) months of her base salary, and provides for additional employment related benefits for Ms. Boenisch.
The summary of the Missling Amendment and the Boenisch Amendment provided herein is qualified in their entirety by the terms of such agreement, which are fully set forth and attached hereto as Exhibits 10.1 and 10.2, respectively, and which are incorporated by reference herein.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
| EXHIBIT NO. | DESCRIPTION | LOCATION | |||
| 10.1 | Fourth Amendment to Employment Agreement by and between Anavex Life Sciences Corp. and Christopher Missling, PhD, dated July 3, 2025 | Filed herewith | |||
| 10.2 | Third Amendment to Employment Agreement by and between Anavex Life Sciences Corp. and Sandra Boenisch, dated July 3, 2025 | Filed herewith | |||
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| ANAVEX LIFE SCIENCES CORP. | ||
| By: | /s/ Christopher Missling | |
| Name: Christopher Missling, PhD Title: Chief Executive Officer | ||
Date: July 3, 2025